Tumor necrosis factor-α-induced cell death in U373 cells overexpressing α-synuclein

Journal of Neuroscience Research

Volumn 73, Issue 3, 2003, Pages 334-340

  Stefanova, Nadia ^a   Schanda, Kathrin ^a   Klimaschewski, Lars ^a   Poewe, Werner ^a   Wenning, Gregor K ^a   Reindl, Markus ^a  

^a UNIVERSITY OF INNSBRUCK   (Austria)

Author keywords

synuclein; Apoptosis; Glia; TNF ; U373

Indexed keywords

ALPHA SYNUCLEIN; CASPASE; GREEN FLUORESCENT PROTEIN; RED FLUORESCENT PROTEIN; TUMOR NECROSIS FACTOR ALPHA;

APOPTOSIS; ARTICLE; ASTROCYTOMA CELL; CARBOXY TERMINAL SEQUENCE; CELL ACTIVATION; CELL INCLUSION; CYTOSKELETON; DEGENERATIVE DISEASE; ENZYME ACTIVATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; NERVE CELL NECROSIS; NUCLEOTIDE SEQUENCE; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SHY DRAGER SYNDROME;

ALPHA-SYNUCLEIN; ANTINEOPLASTIC AGENTS; APOPTOSIS; BRAIN NEOPLASMS; CYTOSKELETON; GENE EXPRESSION; GLIOBLASTOMA; HUMANS; NERVE TISSUE PROTEINS; SYNUCLEINS; TRANSFECTION; TUMOR CELLS, CULTURED; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0042672746     PISSN: 03604012     EISSN: None     Source Type: Journal    
DOI: 10.1002/jnr.10662     Document Type: Article

References (41)

1. Aloe L, Fiore M. 1997. TNF-alpha expressed in the brain of transgenic mice lowers central tyroxine hydroxylase immunoreactivity and alters grooming behavior. Neurosci Lett 238:65-68.
2. Boka G, Anglade P, Wallach D, Javoy-Agid F, Agid Y, Hirsch EC. 1994. Immunocytochemical analysis of tumor necrosis factor and its receptors in Parkinson's disease. Neurosci Lett 172:151-154.
3. Burke RE. 1998. Programmed cell death and Parkinson's disease. Mov Disord 13(Suppl 1):17-23.
4. Crowther RA, Jakes R, Spillantini MG, Goedert M. 1998. Synthetic filaments assembled from C-terminally truncated alpha-synuclein. FEBS Lett 436:309-312.
5. da Costa CA, Ancolio K, Checler F. 2000. Wild-type but not Parkinson's disease-related ala-53→Thr mutant alpha-synuclein protects neuronal cells from apoptotic stimuli. J Biol Chem 275:24065-24069.
6. Dickson DW, Lin W, Liu WK, Yen SH. 1999. Multiple system atrophy: a sporadic synucleinopathy. Brain Pathol 9:721-732.
7. Duda JE, Giasson BI, Gur TL, Montine TJ, Robertson D, Biaggioni I, Hurtig HI, Stern MB, Gollomp SM, Grossman M, Lee VM, Trojanowski JQ. 2000. Immunohistochemical and biochemical studies demonstrate a distinct profile of alpha-synuclein permutations in multiple system atrophy. J Neuropathol Exp Neurol 59:830-841.
8. Engelender S, Kaminsky Z, Guo X, Sharp AH, Amaravi RK, Kleiderlein JJ, Margolis RL, Troncoso JC, Lanahan AA, Worley PF, Dawson VL, Dawson TM, Ross CA. 1999. Synphilin-1 associates with alpha-synuclein and promotes the formation of cytosolic inclusions. Nat Genet 22:110-114.
9. Granville DJ, Carthy CM, Hunt DW, McManus BM. 1998. Apoptosis: molecular aspects of cell death and disease. Lab Invest 78:893-913.
10. Hirsch EC, Hunot S, Damier P, Faucheux B. 1998. Glial cells and inflammation in Parkinson's disease: a role in neurodegeneration? Ann Neurol 44:S115-120.
11. Hsu LJ, Sagara Y, Arroyo A, Rockenstein E, Sisk A, Mallory M, Wong J, Takenouchi T, Hashimoto M, Masliah E. 2000. Alpha-synuclein promotes mitochondrial deficit and oxidative stress. Am J Pathol 157:401-410.
12. Hunot S, Dugas N, Faucheux B, Hartmann A, Tardieu M, Debre P, Agid Y, Dugas B, Hirsch EC. 1999. FcepsilonRII/CD23 is expressed in Parkinson's disease and induces, in vitro, production of nitric oxide and tumor necrosis factor-alpha in glial cells. J Neurosci 19:3440-3447.
13. Iwata A, Maruyama M, Kanazawa I, Nukina N. 2001. Alpha-synuclein affects the MAPK pathway and accelerates cell death. J Biol Chem 276:45320-45329.
14. Kanda S, Bishop JF, Eglitis MA, Yang Y, Mouradian MM. 2000. Enhanced vulnerability to oxidative stress by alpha-synuclein mutations and C-terminal truncation. Neuroscience 97:279-284.
15. Lee M, Hyun D, Halliwell B, Jenner P. 2001. Effect of the overexpression of wild-type or mutant alpha-synuclein on cell susceptibility to insult. J Neurochem 76:998-1009.
16. MacFarlane M, Merrison W, Dinsdale D, Cohen GM. 2000. Active caspases and cleaved cytokeratins are sequestered into cytoplasmic inclusions in TRAIL-induced apoptosis. J Cell Biol 148:1239-1254.
17. McGuire SO, Ling ZD, Lipton JW, Sortwell CE, Collier TJ, Carvey PM. 2001. Tumor necrosis factor alpha is toxic to embryonic mesencephalic dopamine neurons. Exp Neurol 169:219-230.
18. McLean PJ, Kawamata H, Hyman BT. 2001. Alpha-synuclein-enhanced green fluorescent protein fusion proteins form proteasome sensitive inclusions in primary neurons. Neuroscience 104:901-912.
19. McNaught KS, Mytilineou C, Jnobaptiste R, Yabut J, Shashidharan P, Jennert P, Olanow CW. 2002. Impairment of the ubiquitin-proteasome system causes dopaminergic cell death and inclusion body formation in ventral mesencephalic cultures. J Neurochem 81:301-306.
20. Mogi M, Harada M, Riederer P, Narabayashi H, Fujita K, Nagatsu T. 1994. Tumor necrosis factor-alpha (TNF-alpha) increases both in the brain and in the cerebrospinal fluid from parkinsonian patients. Neurosci Lett 165:208-210.
21. Ostrerova N, Petrucelli L, Farrer M, Mehta N, Choi P, Hardy J, Wolozin B. 1999. Alpha-synuclein shares physical and functional homology with 14-3-3 proteins. J Neurosci 19:5782-5791.
22. Ostrerova-Golts N, Petrucelli L, Hardy J, Lee JM, Farer M, Wolozin B. 2000. The A53T alpha-synuclein mutation increases iron-dependent aggregation and toxicity. J Neurosci 20:6048-6054.
23. Park SM, Jung HY, Chung KC, Rhim H, Park JH, Kim J. 2002. Stress-induced aggregation profiles of GST-alpha-synuclein fusion proteins: role of the C-terminal acidic tail of alpha-synuclein in protein thermosolubility and stability. Biochemistry 41:4137-4146.
24. Probst-Cousin S, Rickert CH, Schmid KW, Gullotta F. 1998. Cell death mechanisms in multiple system atrophy. J Neuropathol Exp Neurol 57:814-821.
25. Saha AR, Ninkina NN, Hanger DP, Anderton BH, Davies AM, Buchman VL. 2000. Induction of neuronal death by alpha-synuclein. Eur J Neurosci 12:3073-3077.
26. Schwarz J, Weis S, Kraft E, Tatsch K, Bandmann O, Mehraein P, Vogl T, Oertel WH. 1996. Signal changes on MRI and increases in reactive microgliosis, astrogliosis, and iron in the putamen of two patients with multiple system atrophy. J Neurol Neurosurg Psychiatry 60:98-101.
27. Seo JH, Rah JC, Choi SH, Shin JK, Min K, Kim HS, Park CH, Kim S, Kim EM, Lee SH, Lee S, Suh SW, Suh YH. 2002. Alpha-synuclein regulates neuronal survival via Bcl-2 family expression and PI3/Akt kinase pathway. FASEB J 16:1826-1828.
28. Serpell LC, Betriman J, Jakes R, Goedert M, Crowther RA. 2000. Fiber diffraction of synthetic alpha-synuclein filaments shows amyloid-like cross-beta conformation. Proc Natl Acad Sci USA 97:4897-4902.
29. Souza JM, Giasson BI, Chen Q, Lee VM, Ischiropoulos H. 2000a. Dityrosine cross-linking promotes formation of stable alpha-synuclein polymers. Implication of nitrative and oxidative stress in the pathogenesis of neurodegenerative synucleinopathies. J Biol Chem 275:18344-18349.
30. Souza JM, Giasson BI, Lee VM, Ischiropoulos H. 2000b. Chaperone-like activity of synucleins. FEBS Lett 474:116-119.
31. Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M. 1997. Alpha-synuclein in Lewy bodies. Nature 388:839-840.
32. Sriram K, Matheson JM, Benkovic SA, Miller DB, Luster MI, O'Callaghan JP. 2002. Mice deficient in TNF receptors are protected against dopaminergic neurotoxicity: implications for Parkinson's disease. FASEB J 16: 1474-1476.
33. Stefanis L, Larsen KE, Rideout HJ, Sulzer D, Greene LA. 2001. Expression of A53T mutant but not wild-type alpha-synuclein in PC12 cells induces alterations of the ubiquitin-dependent degradation system, loss of dopamine release, and autophagic cell death. J Neurosci 21:9549-9560.
34. Stefanova N, Klimaschewski L, Poewe W, Wenning GK, Reindl M. 2001. Glial cell death induced by overexpression of alpha-synuclein. J Neurosci Res 65:432-438.
35. Stefanova N, Emgard M, Klimaschewski L, Wenning GK, Reindl M. 2002. Ultrastructure of alpha-synuclein positive aggregations in U373 astrocytoma and rat primary glial cells. Neurosci Lett 323:37-40.
36. Takeda A, Hashimoto M, Mallory M, Sundsumo M, Hansen L, Masliah E. 2000. C-terminal alpha-synuclein immunoreactivicy in structures other than Lewy bodies in neurodegenerative disorders. Acta Neuropathol 99:296-304.
37. Tanaka Y, Engelender S, Igarashi S, Rao RK, Wanner T, Tanzi RE, Sawa A, Dawson V, Dawson TM, Ross CA. 2001. Inducible expression of mutant alpha-synuclein decreases proteasome activity and increases sensitivity to mitochondria-dependent apoptosis. Hum Mol Genet 10:919-926.
38. Thornberry NA, Lazebnik Y. 1998. Caspases: enemies within. Science 281:1312-1316.
39. Togo T, Iseki E, Marui W, Akiyama H, Ueda K, Kosaka K. 2001. Glial involvement in the degeneration process of Lewy body-bearing neurons and the degradation process of Lewy bodies in brains of dementia with Lewy bodies. J Neurol Sci 184:71-75.
40. Vila M, Jackson-Lewis V, Guegan C, Wu DC, Teismann P, Choi DK, Tieu K, Przedborski S. 2001. The role of glial cells in Parkinson's disease. Curr Opin Neurol 14:483-489.
41. Zhou W, Hurlbert MS, Schaack J, Prasad KN, Freed CR. 2000. Overexpression of human alpha-synuclein causes dopamine neuron death in rat primary culture and immortalized mesencephalon-derived cells. Brain Res 866:33-43.